komaroviquinone has been researched along with Chagas-Disease* in 2 studies
2 other study(ies) available for komaroviquinone and Chagas-Disease
| Article | Year |
|---|---|
Synthesis and biological evaluation of quinones derived from natural product komaroviquinone as anti-Trypanosoma cruzi agents.
Current chemotherapy drugs for Chagas' disease are insufficient due to their limited efficacy; however, anti-trypanosomal agents have recently shown promise. As such, synthetic intermediates of komaroviquinone were evaluated for anti-trypanosomal activity. Based on the results, a series of novel quinone derivatives were screened for anti-trypanosomal activity and mammalian cytotoxicity. Several quinone derivatives displayed higher antiprotozoal activity against Trypanosoma cruzi trypomastigotes than the reference drug benznidazole, without concomitant toxicity toward the host cell. Topics: 3T3 Cells; Animals; Chagas Disease; Diterpenes; Humans; Mice; Quinones; Trypanocidal Agents; Trypanosoma cruzi | 2015 |
Antichagasic activity of komaroviquinone is due to generation of reactive oxygen species catalyzed by Trypanosoma cruzi old yellow enzyme.
A novel potent trypanocidal diterpene, komaroviquinone, was reduced by Trypanosoma cruzi old yellow enzyme (TcOYE) to its semiquinone radical. The reductase activity in trypanosome lysates was completely immunoabsorbed by anti-TcOYE antibody. Since TcOYE is expressed throughout the T. cruzi life cycle, komaroviquinone is an interesting candidate for developing new antichagasic drugs. Topics: Animals; Catalysis; Chagas Disease; Diterpenes; Humans; NADPH Dehydrogenase; Quinones; Rabbits; Reactive Oxygen Species; Trypanocidal Agents; Trypanosoma cruzi | 2005 |